Advertisement
U.S. markets closed

Aethlon Medical, Inc. (AEMD)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.6800-0.0500 (-2.89%)
At close: 04:00PM EDT
1.6700 -0.01 (-0.60%)
After hours: 04:05PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.7300
Open1.7400
Bid1.7000 x 1300
Ask1.7300 x 1400
Day's Range1.6700 - 1.7400
52 Week Range1.4000 - 7.2000
Volume14,851
Avg. Volume8,737
Market Cap4.402M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-5.0100
Earnings DateJun 26, 2024 - Jul 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AEMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aethlon Medical, Inc.
    Analyst Report: DaVita Inc.DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
    Rating
    Fair Value
    Economic Moat
    16 hours agoMorningstar
View more
  • PR Newswire

    Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices

    Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices.

  • Insider Monkey

    Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call Transcript

    Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2024 Earnings Call Transcript February 14, 2024 Aethlon Medical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and welcome to the Aethlon Medical Third Quarter Fiscal 2024 Earnings and Corporate Update. [Operator […]

  • Zacks Small Cap Research

    AEMD: Focus on Oncology Studies; In Vitro Binding Study Expected to Advance Clinical Trial Activities

    By M. Marin NASDAQ:AEMD Moving forward towards oncology clinical studies in India & Australia Aethlon Medical (NASDAQ:AEMD) reported 3Q F24 results yesterday and provided a business update, as the company continues to advance research and clinical development activities for medical device, the Hemopurifier®. Under interim CEO James Frakes, the company’s long-standing CFO, AEMD has increased